High-quality bioanalytical capabilities are one of the cornerstones in ADME/DMPK research. Besides providing a wide range of non-clinical ADME-tox and DMPK services, Admescope supports customers’ projects requiring quantitative bioanalysis. Typically, we are focusing on resolving problematic cases through intelligent structure and matrix based analytical method design but analysis by method transfer is also performed routinely.
State-of-the-art analytical equipment combined with the best fitting sample preparation is our philosophy. Best quality results are obtained when all parameters are taken into account, such as the chemistry of the analytes, the used matrix, as well as the PK-study parameters from the study the samples originated from.
Due to the large variety of chemistries of test compounds and the complexity of certain biological matrices, our analytical tool kit is broad and comprises the majority of chromatographic options currently available (reverse phase, HILIC, chiral), and sample preparations range from simple precipitation to complex solid phase extraction combined with chemical derivatisation.
Generally quantitative bioanalysis consists of monitoring known compounds, such as a parent compound and its known metabolites, but unknown metabolites can also be monitored provided the analysis is performed on high resolution mass-spectrometry instrument instead of the typically used, and more sensitive triple-quadrupole instruments favoured for targeted analysis.
As the core field of Admescope is in preclinical drug development, typically the studies require analytical method development. The array of drug candidates we work on ranges from most typical small molecule structures to endogenous small molecules, such as steroids, neurotransmitters and vitamins. Peptides and proteins are also routinely analysed with LC/MS, but if required, biomarkers are also analysed by ELISA. If the project requires radiolabelled chemistry our labs have recently been updated with UPLC-online-radiodetection, liquid scintillation counter and beta microplate reader, as needed.
Our ADME-Tox team members, have lately contributed to scientific publications!
Juha Jyrkäs, Toni Lassila and Ari Tolonen investigated peptide metabolism in vitro and compared various extrahepatic metabolic systems to facilitate selection of the optimal in vitro model for investigating peptide metabolism during drug discovery and development. The interesting piece of research was published in Journal of Pharmaceutical and Biomedical Analysis, we recommend taking a look!
Besides this, the team contributed to a joint publication with academic groups where enzyme activities and expression in human ocular tissues were investigated, and the work was published in Drug Metabolism and Disposition.
